|
Identification and use of treatment (tx) options in patients (pts) with advanced non-small cell lung cancer (aNSCLC) after comprehensive genomic profiling (CGP): A real-world study. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Novartis; Roche |
Other Relationship - Roche |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Takeda |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Takeda |
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Genentech/Roche (Inst); Ignyta (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
|
Stock and Other Ownership Interests - Roche |
Other Relationship - Roche |
|
|
|
Stock and Other Ownership Interests - Abbott; Celgene; Genentech; Regeneron; Roche |
Other Relationship - Roche |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Genentech/Roche |
Other Relationship - Roche |
|
|
|
Other Relationship - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
Other Relationship - Roche |
|
|
|
Stock and Other Ownership Interests - Roche; Xip Diagnostics (I) |
Other Relationship - Roche |
|
|
Leadership - European Medicines Agency (I); Genomica |
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sysmex |
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca Spain; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche |
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I) |